Suitability of Metastatic Lung Tumors for Stereotactic Body Radiotherapy.
Cancer Invest
; 40(4): 378-386, 2022 Apr.
Article
en En
| MEDLINE
| ID: mdl-34894945
ABSTRACT
We investigated factors influencing local control of lung metastases treated with stereotactic body radiotherapy (SBRT) and determined the type of lesions for which SBRT is more suitable. Ninety-six patients and 196 tumors were included. Median follow-up duration was 32.0 months (range 4.7-95.8). The two-year local recurrence rate was 15.2% (95% confidence interval 10.2-21.3). Multivariate analysis revealed biological effective dose, ultracentral tumor location, reirradiation, and prior chemotherapy as significant factors. SBRT is suitable for lung metastases, especially for peripheral tumors and those located in the inner lung parenchyma. For ultracentral lesions and recurrent lesions after SBRT, metastasectomy is recommended.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Radiocirugia
/
Neoplasias Pulmonares
Tipo de estudio:
Observational_studies
Idioma:
En
Revista:
Cancer Invest
Año:
2022
Tipo del documento:
Article